Table 1 Clinicopathological features of 42 patients with recurrence of hormone receptor-positive/HER2 negative breast cancer not receiving chemotherapy
Parameters | Number of all patients (n = 42) (%) |
|---|---|
Age at operation (years old) | Median 59 (range 37–79) |
Tumor size (mm) | Median 20.5 (range 9.5–49.3) |
Pathological lymph node metastasis | |
pN0/pN1mi/pN1a | 32 (76.2%)/3 (7.1%)/7 (16.7%) |
Estrogen receptor | |
Negative/positive | 1 (2.4%)/41 (97.6%) |
Progesterone receptor | |
Negative/positive | 3 (7.1%)/39 (92.9%) |
Ki67 | |
 ≤ 20%/ > 20% | 35 (83.3%)/7 (16.7%) |
Surgical treatment | |
Breast conserving treatment and adjuvant radiation therapy/mastectomy | 18 (42.9%)/24 (57.1%) |
Lymphatic invasion | |
ly0/ly1 | 21 (50.0%)/21 (50.0%) |
Venous invasion | |
v0/v1 | 39 (92.9%)/3 (7.1%) |
Nuclear grade | |
1/2/3 | 20 (47.6%)/16 (38.1%)/6 (14.3%) |
Adjuvant endocrine therapy | |
TAM/TAM + LH-RH agonist/ANA | 10 (23.8%)/7 (16.7%)/25 (59.5%) |
Disease free survival (days) | 1462 (132–3300) |
Primary recurrence site | |
Local/regional lymph node/lung/bone/liver/bone + liver | 18 (42.9%)/13 (30.9%)/7 (16.6%)/1 (2.4%)/1 (2.4%)/2 (4.8%) |
TILs density | |
Absent/ ≤ 10%/ > 10% | 6 (14.3%)/30 (71.4%)/6 (14.3%) |